Cahill Financial Advisors’s DexCom DXCM Stock Holding History

Cahill Financial Advisors’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-180	Closed	-$25K	–	376
2021 Q3	$25K	Buy	+180	New	+$22.7K	0.01%	420

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cahill Financial Advisors's DXCM Position: Q4 2021 in Review

Cahill Financial Advisors sold out of DexCom (DXCM) in Q4 2021, closing a stake of 180 shares — an estimated $25K sold.

Cahill Financial Advisors first reported a position in DXCM in Q3 2021 and held it in 1 quarter. The position peaked at $25K in Q3 2021. 930 funds tracked by Wall St. Rank hold DXCM as of Q4 2021.

Cahill Financial Advisors reported no remaining DexCom position as of Q4 2021 after selling out during the quarter.
Cahill Financial Advisors sold 180 DexCom shares in Q4 2021, an estimated $25K.
Cahill Financial Advisors first reported a position in DexCom in Q3 2021 and held it in 1 quarter.
Cahill Financial Advisors's DexCom position peaked at $25K in Q3 2021.
930 funds tracked by Wall St. Rank held DexCom as of Q4 2021.

Based on Cahill Financial Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.